Cargando…

Reply to “Key Points to Consider When Evaluating Andexxa for Formulary Addition”

Detalles Bibliográficos
Autor principal:	Mahan, Charles E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392924/ https://www.ncbi.nlm.nih.gov/pubmed/32572822 http://dx.doi.org/10.1007/s12028-020-01008-z

Ejemplares similares

A prospective analysis of adverse effects of antiretroviral agents: Additional points to consider
por: Shah, Megha
Publicado: (2010)

Apixaban returned to CVS Caremark formulary after outcry
por: Waldron, Beth
Publicado: (2022)

Reply to “Methodological notes, should be considered in research on Mizaj”
por: Aghanouri, Zahra, et al.
Publicado: (2021)

Complexities to consider when communicating risk of COVID-19
por: Skovdal, M., et al.
Publicado: (2020)

When to use frovatriptan in migraine? A reply
por: Fierro, Brigida, et al.
Publicado: (2011)

REPLY: Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy
por: Aziz-Bose, Rahela, et al.
Publicado: (2023)

Reply to Pediatric optic neuritis: Points to ponder
por: Khadse, Rutika, et al.
Publicado: (2017)

Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine
por: Pijpers, Judith A, et al.
Publicado: (2020)

Reply to Dorgham et al., “Considering Personalized Interferon Beta Therapy for COVID-19”
por: Davoudi-Monfared, Effat, et al.
Publicado: (2021)

Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”
por: Akpinar, Ilke, et al.
Publicado: (2017)

Tread carefully when considering vulvar melanoma in a child or adolescent
por: Morrel, Beth, et al.
Publicado: (2023)

Should medical students learn to develop a personal formulary?: An international, multicentre, randomised controlled study
por: De Vries, T. P. G. M., et al.
Publicado: (2008)

In Reply to “Fertility Preservation in Young Adult Patients With Rectal Cancer: A Few Things to Consider”
por: Stal, Julia, et al.
Publicado: (2022)

Reply to Letter to the Editor Titled “Before Blaming Legionella for Severe Rhabdomyolysis, Consider Alternative Triggers”
por: Gopalakrishna, Harish, et al.
Publicado: (2023)

Reply: Dietary acrylamide and cancer risk: additional data on coffee
por: Mucci, L A, et al.
Publicado: (2003)

What Are Prior Authorization and the Formulary Exception Process?
por: Curtiss, Frederic R.
Publicado: (2005)

Author’s Reply—COVID-19 vaccination and torsades de pointes
por: Abrich, Victor, et al.
Publicado: (2022)

Reply: Lecanemab: turning point, or status quo? An ethics perspective
por: Hardy, John, et al.
Publicado: (2023)

Reply to: Consider the genetic and myopathic background, familial occurrence, and alternative definitions of left ventricular hypertrabeculation/noncompaction
por: Ali, Sulafa K.M.
Publicado: (2015)

What the neuroradiologist should additionally consider in SARS-CoV-2 infection
por: Finsterer, J., et al.
Publicado: (2020)

Cost of Contraceptive Implant Removal Services Must Be Considered When Responding to the Growing Demand for Removals
por: Sergison, Jill E, et al.
Publicado: (2017)

Ophthalmologic implications to consider when using hydroxychloroquine to treat COVID-19 and induced arthritis
por: Zeppieri, Marco
Publicado: (2023)

HIV-Related Knowledge in PLHIV: Issues to Consider in the Indian Context—A Reply to Banagi Yathiraj et al
por: Basu, Saurav
Publicado: (2018)

[Translated article] Reply to “COVID-19 and smoking: An opportunity to quit...when vaccinated!”()
por: Pastor Esplá, Esther, et al.
Publicado: (2022)

AMCP Format for Formulary Submissions, Version 4.0
por: Pannier, Alan, et al.
Publicado: (2016)

Auscultation of the respiratory system — some additional points
por: Ray, Animesh
Publicado: (2015)

The Authors' Reply to “The Addition of Prophylactic Antibiotics Can Achieve a Favorable Outcome”
por: Kaito, Satoshi, et al.
Publicado: (2019)

A Case of Next-generation Sequencing Gene Testing: Points to be Considered in Testing and Reporting
por: Kim, Na-Kyoung, et al.
Publicado: (2022)

Reply to: “Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered”
por: Mallet, Vincent
Publicado: (2021)

Geographical genetic variability: a factor to consider when assessing clinical implications of PRDM9
por: Alemany-Schmidt, Alexandra, et al.
Publicado: (2014)

Reply to the brief communication “Essential review points on the retrospective study of osteoradionecrosis in the jaws”
por: Manzano, Brena Rodrigues, et al.
Publicado: (2020)

Point-of-care ultrasound: reply to Andronikou et al. and Györgyi et al.
por: Arthurs, Owen J., et al.
Publicado: (2021)

Reply to: A key role for vitamin D binding protein in COVID-19?
por: Arab-Ahmadi, Mehran, et al.
Publicado: (2021)

When being good is missing the point: Closing the loop
por: Ianchulev, Stefan A., et al.
Publicado: (2016)

Reply: Point the microscope toward the educator
por: Okereke, Ikenna
Publicado: (2021)

Were Additional Treatments Affecting Pharmacokinetics Administered after Raltegravir Overdosing?: Authors' Reply
por: Hosoda, Tomohiro, et al.
Publicado: (2020)

The Authors' Reply to “Additional Bacteriological Examinations Might be Required for the Correct Identification of Staphylococcus warneri”
por: Yamamoto, Junpei, et al.
Publicado: (2020)

Is the Completion Time of a Questionnaire a Pivotal Factor When Proving Feasibility?: Author's Reply
por: Nonaka, Takashi, et al.
Publicado: (2013)

The Authors Reply
por: Pike, Mindy M., et al.
Publicado: (2020)

Reply
por: Forrer, F., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_pvtfcoalg3uj467n0bi5a9uqja